



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SCH-23390 hydrochloride

Cat. No.:	HY-19545A
CAS No.:	125941-87-9
Molecular Formula:	C ₁₇ H ₁₉ Cl ₂ NO
Molecular Weight:	324.24
Target:	Dopamine Receptor; 5-HT Receptor; Potassium Channel
Pathway:	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 32 mg/mL (98.69 mM) H ₂ O : 28.57 mg/mL (88.11 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown.				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	3.0841 mL	15.4207 mL	30.8414 mL
		5 mM	0.6168 mL	3.0841 mL	6.1683 mL
		10 mM	0.3084 mL	1.5421 mL	3.0841 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.42 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	SCH-23390 hydrochloride (R-(+)-SCH-23390 hydrochloride) is a potent and selective dopamine D ₁ -like receptor antagonist with K _i s of 0.2 nM and 0.3 nM for the D ₁ and D ₅ receptor, respectively. SCH-23390 hydrochloride is a potent and high efficacy human 5-HT _{2C} receptor agonist with a K _i of 9.3 nM. SCH-23390 hydrochloride also binds with high affinity to the 5-HT ₂ and 5-HT _{1C} receptors. SCH-23390 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC ₅₀ of 268 nM ^{[1][2][3]} .			
IC ₅₀ & Target	D ₁ Receptor 0.2 nM (K _i)	D ₅ Receptor 0.3 nM (K _i)	5-HT _{2C} Receptor 9.3 nM (K _i)	GIRK 268 nM (IC ₅₀)
In Vitro	SCH-23390 (1 μM) treatment reverses the inhibitory effects of Isosibiricin on NLRP3 expression and the cleavages of caspase-1 and IL-1β in the LPS-induced BV-2 cells. SCH-23390 could reverse the Isosibiricin-mediated inhibition of the NLRP3/caspase-1 inflammasome pathway ^[4] .			

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SCH-23390 can abolish generalized seizures evoked by the chemoconvulsants. SCH-23390 has also been used in studies of other neurological disorders in which the dopamine system has been implicated, such as psychosis and Parkinson's disease. Apart from the study of neurological disorders, SCH-23390 has been extensively used as a tool in the topographical determination of brain D₁ receptors in rodents, nonhuman primates, and humans^[1].

SCH-23390 is a very short-acting compound with an elimination half-life of around 25 min following administration of 0.3 mg/kg i.p. in the rat^[1].

SCH-23390 augments dopamine-induced ductus constriction in CD-1 mouse vessels under newborn O₂ conditions^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[5]

Rats: All rats receive acclimatization saline injections the two afternoons 1 prior to 2 their test day. At the end of the Training phase, rats (n=15 or 16 rats/group) are assigned to one 3 of three conditions (0, 1, or 10 µg/kg IP injections of SCH 23390). The day following the Training phase, rats are tested in the operant 6 conditioning chambers for saccharin cue-reactivity (saccharin seeking)^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2020 Feb 18;11(1):941.
- Microbiome. 2020 Aug 20;8(1):120.
- Int J Biol Macromol. 2023 Jul 4;125703.
- Acta Pharmacol Sin. 2020 Feb;41(2):173-180.
- Int Immunopharmacol. 2020 Nov;88:106963.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Bourne JA, et al . SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev. 2001 Winter;7(4):399-414.
- [2]. Millan MJ, et al. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl). 2001 Jun;156(1):58-62.
- [3]. Kuzhikandathil EV, et al. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol. 2002 Jul;62(1):119-26.
- [4]. Wang YH, et al. Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway. Acta Pharmacol Sin. 2020 Feb;41(2):173-180.
- [5]. Crockett SL, et al. Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness. Pediatr Res. 2019 Dec 9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA